Saturday 17 October 2026
Export TNDM’s income statement to Excel — free account
Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.
16.17
0.35
−2.12%
Follow TNDM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.00 | 1.28 | 1.46 | 0.82 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(30.07) | 118.62 | 151.08 | 99.38 | |
P/B ratio |
7.99 | 9.90 | 9.53 | 6.18 | |
Price to Tangible BV |
8.04 | 9.97 | 9.59 | 6.22 | |
EV/Sales |
1.14 | 1.31 | 1.47 | 0.81 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(215.09) | 68.47 | (153.92) | (92.32) | |
EV/FCF |
(12.40) | (18.43) | (15.13) | (8.61) | |
Quick Ratio |
2.44 | 2.87 | 1.89 | 1.76 | |
Current Ratio |
3.18 | 3.58 | 2.55 | 2.44 | |
Net Debt/EBITDA |
(15.29) | (2.41) | 1.51 | 0.52 | |
Debt/Assets |
52.21% | 52.17% | 35.19% | 35.40% | |
Debt/Equity |
4.62 | 4.55 | 2.00 | 2.33 | |
Asset Turnover |
1.03 | 0.99 | 1.10 | 1.10 | |
Operating CF/Net income |
1.64 | (0.54) | (16.62) | (0.39) | |
Capex/Depreciation |
(0.96) | (1.45) | (2.09) | (0.88) | |
Interest Coverage |
(5.63) | (7.91) | 4.00 | (11.07) | |
Research and Development Expense of Revenue |
18.44% | 18.62% | 15.86% | 19.54% | |
Selling, General and Administrative Expense of Revenue |
43.86% | 43.76% | 38.95% | 43.51% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.18% | 6.33% | 6.93% | 8.48% | |
Graham Net Nets |
(0.21) | (0.10) | (0.07) | (0.15) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.16%) | (7.30%) | (13.97%) | (25.12%) | |
Free Cash Flow Yield |
(9.20%) | (5.56%) | (6.69%) | (11.49%) | |
Revenue per Share |
3.69 | 3.61 | 4.32 | 3.68 | |
Operating CF per Share |
(0.50) | 0.16 | 0.15 | 0.12 | |
Capex per Share |
(0.06) | (0.09) | (0.10) | (0.06) | |
Free Cash Flow per Share |
(0.56) | 0.07 | 0.05 | 0.06 | |
Cash per Share |
6.61 | 8.34 | 4.35 | 4.72 | |
Shareholders Equity per Share |
1.89 | 1.94 | 2.31 | 1.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.89 | 1.94 | 2.31 | 1.97 | |
Free Cash Flow |
(38.68) | 4.79 | 3.10 | 4.17 | |
Working Capital |
551.63 | 639.14 | 375.42 | 364.40 | |
Capital Expenditures |
(4.05) | (6.27) | (6.68) | (4.09) | |
Net Current Asset Value |
(219.17) | (133.89) | (107.80) | (124.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
145.25 | 133.62 | 140.04 | 116.56 | |
Average Payables |
59.98 | 59.83 | 45.90 | 48.12 | |
Average Inventory |
138.84 | 133.78 | 139.19 | 144.86 | |
Average Assets |
1,014.97 | 1,037.77 | 924.39 | 916.19 | |
Average Common Equity |
131.84 | 143.85 | 209.13 | 185.34 |
Columns are period end dates